Accelerating your journey to clinic is crucial in life sciences, where speeding project timelines can make all the difference. Optimer offers an antibody alternative that can cut up to 75% (2.8 years) off the time to clinic compared to standard antibodies, helping you bring diagnostic and therapeutic solutions to market faster.

Find out how Optimer compare to antibodies, to deliver:

• A faster path to clinic
• A simpler path to clinic with less room for error
• A more consistent product for less waste in the product lifecycle
• The ability to pursue new targets for novel diagnostics and therapeutics
• Low immunogenic molecules for optimal therapeutic profiles
• High quality, non-animal derived reagents for adherence to directive 2010/63/EU

Download the whitepaper to find out how you could cut valuable years from discovery and development with Optimer.

Tags